Edition:
United Kingdom

People: Nicox SA (NCOX.PA)

NCOX.PA on Paris Stock Exchange

9.76EUR
23 Feb 2018
Change (% chg)

-- (--)
Prev Close
€9.76
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
210,714
52-wk High
€13.68
52-wk Low
€7.65

Spencer, Gavin 

Dr. Gavin Spencer has been Executive Vice President Corporate Development and Member of the Management Committee of NicOx SA since January 2009. Before that, he has been Vice President – Business Development at the Company since 2005. Dr. Spencer has been with Nicox since 2005 and has been key in building and managing the partnerships, including closing the 2006 Pfizer deal and the 2010 Bausch+Lomb deal. He has also been responsible for identifying ophthalmology opportunities including the 2012 deal with RPS and his team has led the design and communication of the new Nicox corporate identity. Gavin Spencer has a Doctorate in Philosophy in Chemistry from the University of Aberdeen, Scotland. He has over 18 years of experience in the industry, including product development, search, evaluation and licensing of new technologies, alliance management, communications and M&A evaluation. Before joining Nicox he fullfilled roles in the search, evaluation and development of new technologies at Novartis Consumer Health in Nyon, Switzerland, where he was responsible for the search, evaluation and development of new technologies and began his career in the development and evaluation of new products at Boots Healthcare International in the UK.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --